- Home
- URGN vs MCRI Comparison
URGN vs MCRI Comparison
Compare URGN & MCRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | URGN | MCRI |
|---|---|---|
| Founded | 2004 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2016 | 1996 |
Fundamental Metrics
Financial Performance| Metric | URGN | MCRI |
|---|---|---|
| Price | $40.70 | $115.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 6 |
| Target Price | $60.00 | ★ $127.00 |
| AVG Volume (30 Days) | ★ 579.2K | 108.4K |
| Earning Date | 11-05-2026 | 10-20-2026 |
| Dividend Yield | N/A | ★ 1.04% |
| EPS Growth | N/A | ★ 41.41 |
| EPS | N/A | ★ 1.52 |
| Revenue | $1,128,000.00 | ★ $395,377,000.00 |
| Revenue This Year | $193.48 | $4.78 |
| Revenue Next Year | $68.06 | $1.90 |
| P/E Ratio | ★ N/A | $76.85 |
| Revenue Growth | N/A | ★ 114.40 |
| 52 Week Low | $15.86 | $88.13 |
| 52 Week High | $50.81 | $135.93 |
Technical Indicators
Market Signals| Indicator | URGN | MCRI |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 33.42 |
| Support Level | $40.94 | $112.85 |
| Resistance Level | $44.63 | $127.17 |
| Average True Range (ATR) | 1.63 | 2.60 |
| MACD | -0.23 | -0.52 |
| Stochastic Oscillator | 23.37 | 0.00 |
Price Performance
Historical ComparisonAbout URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.